These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25231694)

  • 1. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
    Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
    Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
    Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs.
    Ohta A; Kato H; Murayama K; Hashimoto E; Murakami M; Nishine A; Ohshige T; Sada Y; Asai S; Kawata T; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2014; 61(1):13-8. PubMed ID: 24064478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
    Harashima SI; Tanaka D; Yamane S; Ogura M; Fujita Y; Murata Y; Seike M; Koizumi T; Aono M; Wang Y; Inagaki N
    Horm Metab Res; 2013 Mar; 45(3):231-8. PubMed ID: 22972180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
    Takahara M; Shiraiwa T; Kaneto H; Katakami N; Matsuoka TA; Shimomura I
    Endocr J; 2012; 59(12):1131-6. PubMed ID: 22850206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Williams-Herman D; Xu L; Teng R; Golm GT; Johnson J; Davies MJ; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Jan; 14(1):67-76. PubMed ID: 22050786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.
    Sudhakaran C; Kishore U; Anjana RM; Unnikrishnan R; Mohan V
    Diabetes Technol Ther; 2011 Jan; 13(1):27-32. PubMed ID: 21175268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
    Yoon KH; Shockey GR; Teng R; Golm GT; Thakkar PR; Meehan AG; Williams-Herman DE; Kaufman KD; Amatruda JM; Steinberg H
    Int J Clin Pract; 2011 Feb; 65(2):154-64. PubMed ID: 21235696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.